From: Long-term follow-up of cytogenetically normal CEBPA-mutated AML
 | OS | RFS | ||||
---|---|---|---|---|---|---|
 | HR | 95% CI | p | HR | 95% CI | p |
biCEBPA versus moCEBPA (univariable analysis) | 0.4 | 0.2-0.8 | 0.008 | 0.5 | 0.2-0.9 | 0.021 |
biCEBPA versus moCEBPA (adjusted for FLT3-ITD) | 0.4 | 0.2-0.8 | 0.006 | 0.5 | 0.2-0.9 | 0.021 |
biCEBPA versus moCEBPA (adjusted for FLT3-TKD) | 0.4 | 0.2-0.8 | 0.012 | 0.4 | 0.2-0.9 | 0.018 |
biCEBPA versus moCEBPA (adjusted for FLT3-ITD and FLT3-TKD) | 0.4 | 0.2-0.8 | 0.006 | 0.4 | 0.2-0.8 | 0.012 |
biCEBPA versus moCEBPA (adjusted for FLT3-ITD, NPM1 mutations and interaction NPM1/FLT3-ITD) | 0.2 | 0.1-0.5 | <0.001 | 0.2 | 0.1-0.6 | 0.003 |
biCEBPA versus moCEBPA (adjusted for NPM1 mutations) | 0.2 | 0.1-0.5 | <0.001 | 0.2 | 0.1-0.6 | 0.002 |
biCEBPA versus moCEBPA (adjusted for PINAOS or PINARFS (both without biCEBPA)) | 0.2 | 0.1-0.4 | <0.001 | 0.2 | 0.1-0.6 | 0.001 |